{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-25-000051","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.095744+00:00","generated_at":"2026-05-20T03:14:30.306194+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"low","headline":"Context Therapeutics updates corporate presentation for June 2025","bullets":["Company issued an updated corporate presentation dated June 2025.","Presentation emphasizes T cell engager platform for solid tumors.","Slide 17 of the presentation is incorporated by reference under Item 8.01.","No clinical data, financial results, or guidance were disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-25-000051","json":"https://secwatch.observer/filing/0001842952-25-000051.json","markdown":"https://secwatch.observer/filing/0001842952-25-000051.md","text":"https://secwatch.observer/filing/0001842952-25-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000051/0001842952-25-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000051/cntx-20250602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:14:30.306194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}